🔎 Trials Near Me

Domov › Burkittov limfom › Pennsylvania

Klinične študije za Burkittov limfom v Pennsylvania

18 študij za Burkittov limfom išče udeležence na lokacijah v Pennsylvania.

Mesta v Pennsylvania

Uradno besedilo študije (angleško)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Penn State Children's Hospital, Hershey
  • Children's Hospital of Philadelphia, Philadelphia
  • in še 2
Vključevanje udeležencevFaza 2
366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Lehigh Valley Hospital - Muhlenberg, Bethlehem
  • University of Pennsylvania/Abramson Cancer Center, Philadelphia
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18–39 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT03150693

Blinatumomab Consolidation in Real World

  • University of Pennsylvania, Philadelphia
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07117136

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevOpazovalna študija
Starost 0–38 · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06131801

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • in še 2
Vključevanje udeležencevFaza 2
365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Penn State Hershey Medical Center, Hershey
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

  • Children's Hospital of Philadelphia (Data Collection Only), Philadelphia
Vključevanje udeležencevFaza 3
Starost 1 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07223021

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Vključevanje udeležencevFaza 1/2
6 Months – 25 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevFaza 1
Starost 0–18 · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT06173518

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • in še 3
Vključevanje udeležencevFaza 2
Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • in še 3
Vključevanje udeležencevFaza 3
365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevFaza 2
Starost 7–25 · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05082519

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

  • UPMC Hillman Cancer Center, Pittsburgh
Vključevanje udeležencevFaza 1/2
Starost 18 in več · Vsi spoli · Posodobljeno 31. jul. 2026 · NCT07069699

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencev
Do 25 let · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT03810196

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevFaza 1/2
Starost 0–29 · Vsi spoli · Posodobljeno 26. maj 2026 · NCT05480449

Co-administration of CART22-65s and huCART19 for B-ALL

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevFaza 1/2
Do 29 let · Vsi spoli · Posodobljeno 27. mar. 2026 · NCT05674175

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevFaza 1/2
Starost 15–50 · Vsi spoli · Posodobljeno 9. sep. 2025 · NCT04150497

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

  • AHN Cancer Institute - West Penn Hospital, Pittsburgh
Vključevanje udeležencevFaza 2
Starost 18–79 · Vsi spoli · Posodobljeno 13. jan. 2025 · NCT05281809

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.